According to PEdaily.cn, Xunminkang Biotechnology Co., Ltd. ("Xunminkang"), a company focusing on precision diagnosis in clinical microbiology, has got tens of millions of yuan in Series A financing from Xiran Capital. Phoenixtree Capital acted as the exclusive financial consultant. Proceeds from this round will be used for the research and development of products, the establishment of a new technology platform, and the optimization and marketing of existing products.

Founded in 2014, Xunminkang is engaged in the precision diagnosis and treatment of infectious diseases, innovative molecular diagnostic technology research and development, and clinical transformation. The company is one of the earliest enterprises committed to the R&D and application of metagenomic sequencing technology for the detection of pathogenic microorganisms in China.

So far, Xunminkang has independently developed the IngeniSeq® ️ clinical microbial sequencing technology platform, established the database of clinical microbiology and supporting biological information analysis system, covering 20343 types of bacteria, fungi, viruses, parasites and others, for DNA and RNA sequencing of all kinds of clinical samples (cerebrospinal fluid, blood, alveolar lavage fluid, aqueous humor, organization, etc.). The platform can be used in clinical treatment, guide the rational use of anti-infective drugs, and improve prognosis and control nosocomial infection.

In the opinion of Gao Jing, a partner of Xiran Capital, the molecular diagnosis of pathogenic microorganisms is a huge unmet demand in domestic clinical practice, which has been neglected in the past due to various reasons, leading to an obvious gap with the international advanced level. Molecular diagnostic products of pathogenic microorganisms have unique requirements on timeliness, sensitivity and specificity, which are different from other molecular diagnostic products. Those products are used in different departments such as the department of infection, respiration, and neurology. 

Phoenixtree Capital is an emerging investment bank and venture capital firm, focusing on investment banking and investment of early-stage start-ups in the fields of Internet, consumer services, energy, and environmental protection. Headquartered in Shanghai, Phoenixtree Capital now has offices in Beijing, Shenzhen, and Hangzhou. 

Phoenixtree Capital mainly participates in the angel round and Pre-A round investment.